With $GPCR I also feel very comfortable in the depot. I've already taken out the insert there.
Guggenheim left the rating for Structure Therapeutics ADR (NASDAQ: GPCR) at 'buy'. The target price is $140.00 after $90.00 previously.
Prior to this rating there were 15 analyst(s) that rated Structure Therapeutics ADR a 'Buy' and 0 rated it a 'Hold'. There were 0 Sell recommendations.
Analyst consensus estimates and price targets for Structure Therapeutics ADR can be found here. Further news on Structure Therapeutics ADR can be found here.
The Structure Therapeutics ADR share price ended the official trading session at a closing price of $88.64. The stock's performance was up 40.14% in the last month and up 212.77% in the last 12 months.